Core Viewpoint - The company has conducted its 13th meeting of the third supervisory board, where several key resolutions regarding the 2024 stock option incentive plan were approved, including the cancellation of certain stock options and adjustments to the exercise price [1][2][3]. Group 1: Supervisory Board Meeting - The meeting was held on June 30, 2025, with all three supervisors present, and was conducted in accordance with relevant laws and regulations [1]. - The resolutions passed included the cancellation of stock options due to unmet exercise conditions, which aligns with legal requirements and does not harm the interests of the company or its shareholders [1][2]. Group 2: Stock Option Incentive Plan Adjustments - The supervisory board approved adjustments to the exercise price of the stock options, confirming that these changes comply with the relevant regulations and do not negatively impact shareholder interests [2]. - A total of 419,000 stock options will be granted to 33 eligible incentive objects on July 7, 2025, with an exercise price set at 53.49 yuan per option [3]. Group 3: Use of Idle Funds - The board agreed to continue using up to 200 million yuan of idle raised funds for cash management, which is expected to enhance the preservation and appreciation of the company's cash without adversely affecting its operations [3][4].

一、核查的范围与程序 买卖公司股票情况，中国证券登记结算有限责任公司深圳分公司已出具《信息披露义务 人持股及股份变更查询证明》和《股东股份变更明细清单》。 二、核查对象买卖公司股票情况 限定内幕信息知情人范围，采取相应保密措施。公司已将本激励计划的商议筹划、论证 咨询、决策讨论等阶段的内幕信息知情人进行登记，内幕信息知情人严格控制在《内幕 信息知情人登记表》登记的人员范围，未发现信息泄露情况。 证券代码：300844 证券简称：山水比德 公告编号：2025-038 广州山水比德设计股份有限公司 关于 2025 年股票期权激励计划内幕信息知情人买卖公司股票情况的 自查报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州山水比德设计股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日公告实 施 2025 年股票期权激励计划（以下简称"本激励计划"），根据《上市公司股权激励 管理办法》《深圳证券交易所创业板上市公司自律监管指南第 1 号—业务办理》《2025 年股票期权激励计划（草案）》的规定，公司对相关内幕信息知情人在本激励计划公开 披露前 6 ...

Core Points - The announcement details the results of the third exercise period for the stock option incentive plan of Shanghai Pharmaceuticals, indicating that no options were exercised during the second quarter of 2025 [4][11] - The total number of stock options available for the third exercise period is 680,000, with the exercise period running from February 8, 2025, to February 7, 2026 [4][11] - The company has followed all necessary approval procedures for the stock option incentive plan, including independent opinions from directors and the supervisory board [2][3][5] Approval Process - The company’s board approved the stock option incentive plan and its management measures, with independent directors providing their opinions and the supervisory board conducting necessary checks [2][3][5] - The plan was initially approved by the State-owned Assets Supervision and Administration Commission [1][2] Exercise Details - As of the second quarter of 2025, the number of individuals eligible to exercise the options is 20, but none have exercised their options [7][11] - The stock options are to be issued as ordinary shares (A-shares) to the incentive targets [7][9] Impact on Financials - The lack of exercised options during the third exercise period has not had a significant impact on the company's financial status or operating results as of the end of the second quarter of 2025 [11]

Core Viewpoint - The announcement details the first exercise period of the 2024 stock option incentive plan for Tianma Technology Group, allowing eligible participants to exercise a total of 3.8632 million stock options starting from July 9, 2025 [1][5][9]. Summary by Sections Incentive Plan Approval and Implementation - The board of directors approved the stock option incentive plan, which includes a total of 123 eligible participants and a total of 3.8632 million stock options available for exercise [1][9]. - The plan underwent necessary decision-making procedures and disclosures, including independent legal and financial opinions [1][4]. Historical Stock Option Granting - The total number of stock options granted was adjusted from 9.2 million to 10.12 million due to changes in the number of eligible participants and the exercise price was set at 13.60 yuan per option [4][5]. - The number of eligible participants was reduced from 155 to 140 due to resignations and other reasons [4][5]. Conditions for the First Exercise Period - The first exercise period is defined as starting from the authorization date (July 9, 2024) and lasting until July 8, 2025, with a maximum exercise ratio of 40% of the total granted options [5][6]. - The company achieved the performance targets necessary for the exercise conditions, including a revenue growth rate of at least 15% compared to the previous year [6][9]. Specifics of the First Exercise - The exercise quantity is set at 3.8632 million options, with an adjusted exercise price of 13.56 yuan per option [5][6]. - The exercise method is self-exercise, and the options will be sourced from the company's directed issuance of A-shares [5][7]. Financial Accounting for Stock Options - The company will use the Black-Scholes model to determine the fair value of the stock options at the grant date and will amortize the related expenses during the waiting period [8][9]. Verification by Committees - The remuneration and assessment committee confirmed that all 123 participants meet the exercise conditions, and the supervisory board also validated the eligibility of the participants [9][10].

Core Viewpoint - The announcement details the completion of the initial registration for the 2025 stock option incentive plan by Luxshare Precision Industry Co., Ltd, highlighting the approval processes, specific conditions for stock option grants, and the expected impact on the company's financial status [1][2][4]. Group 1: Approval Process - The company has completed the necessary approval procedures for the 2025 stock option incentive plan, which includes the review and approval by the board of directors and the supervisory board [1][2]. - The plan was publicly disclosed, and no objections were raised during the public notice period [1]. Group 2: Stock Option Grant Details - The stock options granted under this plan have a maximum validity of 84 months from the date of the first grant [2]. - The waiting periods for the stock options are set at 12, 24, 36, 48, and 60 months, during which the options cannot be transferred or used as collateral [2]. - The plan specifies that the stock options will be exercisable in five phases, with 20% of the options becoming exercisable at each phase [2]. Group 3: Performance Targets - The performance assessment for the stock options is based on annual revenue targets from 2025 to 2029, with specific revenue goals set for each year [2]. - The revenue targets are as follows: 2025 - 290 billion, 2026 - 320 billion, 2027 - 350 billion, 2028 - 380 billion, and 2029 - 410 billion [2]. Group 4: Impact on Financial Status - The stock option plan is expected to influence the company's financial statements, with costs being amortized over the waiting period based on the fair value of the options [4]. - The incentive plan aims to align the interests of shareholders, the company, and core team members, promoting sustainable and rapid development [4].

Core Viewpoint - The company conducted a self-examination regarding the trading activities of insiders and incentive recipients related to the 2025 stock option incentive plan, confirming no insider trading occurred prior to the public announcement of the plan [1][3]. Group 1: Examination Process - The self-examination covered the period from December 16, 2024, to June 16, 2025, focusing on stock trading activities of insiders and incentive recipients [1]. - The examination was based on information provided by the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, which issued relevant certificates and detailed lists of share changes [2]. Group 2: Trading Activities of Insiders - Six individuals were identified as having engaged in stock trading during the examination period, with two being incentive recipients [2]. - The Chairman and General Manager, Chen Xueming, purchased shares as part of a previously disclosed increase plan, unrelated to insider information regarding the incentive plan [2]. - Other trading activities by five individuals, including two incentive recipients, were based on publicly disclosed information and independent market judgment, with no insider information influencing their trades [2][3]. Group 3: Conclusion of the Examination - The company found no evidence of information leakage or insider trading related to the incentive plan prior to its public disclosure [3]. - The company adhered to strict confidentiality measures and regulations during the planning and discussion phases of the incentive plan [3].

Core Viewpoint - The company has announced the expiration and cancellation of unexercised stock options under its stock option incentive plan, which was effective for 10 years from July 3, 2015, to July 2, 2025 [1][2]. Summary by Sections Stock Option Incentive Plan - The stock option incentive plan was approved by the board and shareholders in 2015, with a validity period of 10 years [1]. - The exercise price of the stock options has been adjusted multiple times, with the final adjustment setting the price at 17.24 yuan per share [1]. Cancellation of Unexercised Stock Options - As of July 2, 2025, the company decided to cancel 37,460 stock options that were granted to 8 incentive recipients but remained unexercised [1]. - The cancellation aligns with the company's stock option incentive plan and relevant regulations [2]. Impact on the Company - The cancellation of the unexercised stock options is not expected to have a material impact on the company's financial status or operational results [1]. Opinions from Committees - The Board's Compensation and Assessment Committee and the Supervisory Committee both agree that the cancellation of the unexercised stock options complies with regulations and the company's incentive plan [2]. Legal Opinion - The legal opinion confirms that the necessary approvals and authorizations for the cancellation have been obtained, in accordance with relevant regulations [3].

Core Viewpoint - The announcement details the stock option incentive plan of Xinjiang Baihua Village Pharmaceutical Group Co., Ltd., highlighting the execution of stock options and the related financial implications for the company [1][9]. Summary by Sections Stock Option Exercise Details - The number of stock options exercised from April 1, 2025, to June 30, 2025, is 149,540 shares, representing 5.90% of the total exercisable stock options. As of June 30, 2025, a total of 2,205,445 shares have been exercised, accounting for 87.06% of the total exercisable stock options [1][9]. - The stock from this exercise will be listed for trading on the second trading day after the exercise date [1]. Decision-Making Process and Disclosure - The decision-making process for the stock option exercise involved several proposals, including the draft of the stock option incentive plan and the management measures for its implementation. Independent directors provided their consent for these matters [2][3]. Adjustments to Incentive Plan - The company has adjusted the list of incentive objects and the number of granted rights, with a total of 1,207,650 stock options being canceled due to non-fulfillment of exercise conditions, reducing the number of incentive objects from 162 to 149 [4][5]. - A total of 2,718,205 stock options were canceled for those who did not meet the exercise conditions, further adjusting the number of incentive objects [6]. Financial Impact and Fundraising - The company raised 744,709.20 yuan from the exercise of 149,540 shares, with a cumulative fundraising of 45,614,409.60 yuan from the total exercised options, which is intended to supplement the company's working capital [9]. - The total number of shares increased from 384,144,335 to 384,293,875, but this change did not significantly impact the company's financial status or operating results [9].

Core Viewpoint - The announcement details the results of the stock option incentive plan for the second quarter of 2025, highlighting the number of shares exercised and the adjustments made to the stock option plan due to various corporate actions [1][2][3]. Group 1: Stock Option Exercise Results - A total of 446,622 shares were exercised by the incentive plan participants, with the shares to be listed for trading on the second trading day after the exercise date [1][6]. - The stock option exercise was conducted under the self-exercise model, and the newly issued shares are unrestricted for trading [6][9]. Group 2: Adjustments to Stock Option Plan - The exercise price for the first grant of options was adjusted from 3.15 CNY/share to 2.28 CNY/share, and for the reserved options from 2.69 CNY/share to 1.82 CNY/share due to the 2021 profit distribution [3][4]. - The company has also canceled unexercised options for individuals who no longer meet the eligibility criteria due to retirement, resignation, or performance issues, totaling 6,251,028 options [4][5]. Group 3: Impact on Share Capital Structure - Following the exercise of options, the total number of shares increased from 15,489,308,117 to 15,489,754,739, reflecting the addition of the exercised shares [9]. - The company raised 446,622 CNY from the exercise, which will be used to supplement its working capital [9][10]. Group 4: Financial Impact - The exercise of stock options is not expected to have a significant impact on the company's financial condition or operating results [10].

Core Viewpoint - The announcement details the results of the stock option incentive plan for the second quarter of 2025, highlighting the execution of the plan and the stock options exercised by the company's employees [1][4]. Summary by Sections Stock Option Incentive Plan Approval and Disclosure - The company has completed the approval procedures and information disclosure for the 2021 stock option incentive plan, including the review of relevant proposals by the board and independent directors [1][2]. - The independent directors provided opinions on the proposals related to the stock option incentive plan [1][3]. Stock Option Exercise Results - For the first grant of stock options under the 2021 incentive plan, 98.59% of the options for the third exercise period were exercised, totaling 110,990 shares [4][10]. - The reserved stock options for the second exercise period saw 99.95% exercised, with a total of 919,500 shares exercised cumulatively [4][10]. - In total, 175,990 shares were exercised in the second quarter of 2025 from both the first grant and reserved stock options [4][10]. Decision Procedures and Information Disclosure - The decision-making process for stock option exercises and the related information disclosure were conducted in accordance with regulations, with no objections raised during the public notice period [4][5]. Changes in Stock Option Prices - The exercise price for the first grant of stock options was adjusted from 9.61 CNY to 8.41 CNY, and for reserved options from 13.44 CNY to 12.24 CNY due to profit distribution plans [5][6]. - Further adjustments were made to the exercise prices in subsequent meetings, reflecting changes in the company's profit distribution [6][7]. Impact on Share Capital Structure - Following the exercise of stock options, the total number of shares increased to 720,546,867, with all newly issued shares being tradable without restrictions [10][11]. - The company confirmed that the actual controller's status remained unchanged after the share issuance [11]. Financial Impact - The stock option exercises are not expected to have a significant impact on the company's financial condition or operating results [12].